Knights of Columbus Asset Advisors LLC Trims Stock Position in Cencora, Inc. (NYSE:COR)

Knights of Columbus Asset Advisors LLC lessened its position in Cencora, Inc. (NYSE:COR - Free Report) by 16.4% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 41,253 shares of the company's stock after selling 8,110 shares during the period. Knights of Columbus Asset Advisors LLC's holdings in Cencora were worth $9,269,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Raymond James Financial Inc. bought a new position in Cencora in the 4th quarter valued at about $322,460,000. Wellington Management Group LLP lifted its holdings in shares of Cencora by 7.0% in the third quarter. Wellington Management Group LLP now owns 5,193,386 shares of the company's stock valued at $1,168,927,000 after purchasing an additional 338,452 shares in the last quarter. Amundi boosted its position in shares of Cencora by 30.8% during the fourth quarter. Amundi now owns 1,338,710 shares of the company's stock valued at $318,385,000 after buying an additional 314,846 shares during the last quarter. Nordea Investment Management AB grew its holdings in Cencora by 40.2% during the fourth quarter. Nordea Investment Management AB now owns 1,077,272 shares of the company's stock worth $243,173,000 after buying an additional 308,773 shares in the last quarter. Finally, Two Sigma Advisers LP grew its holdings in Cencora by 21.7% during the third quarter. Two Sigma Advisers LP now owns 1,638,400 shares of the company's stock worth $368,771,000 after buying an additional 292,600 shares in the last quarter. 97.52% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on COR shares. Mizuho began coverage on shares of Cencora in a report on Wednesday, December 4th. They set an "outperform" rating and a $280.00 price objective on the stock. Wells Fargo & Company boosted their price target on shares of Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a report on Friday, March 14th. JPMorgan Chase & Co. increased their price objective on shares of Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a research note on Friday, January 24th. Evercore ISI lifted their target price on shares of Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a research report on Thursday, February 6th. Finally, StockNews.com raised Cencora from a "hold" rating to a "buy" rating in a report on Wednesday, March 12th. Two investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $280.20.

Remove Ads

Cencora Stock Performance

NYSE COR traded up $2.84 on Wednesday, hitting $271.32. 1,036,117 shares of the stock traded hands, compared to its average volume of 1,380,846. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. The business's fifty day moving average is $251.80 and its two-hundred day moving average is $240.46. Cencora, Inc. has a 12 month low of $214.77 and a 12 month high of $271.74. The firm has a market capitalization of $52.61 billion, a price-to-earnings ratio of 38.59, a PEG ratio of 1.31 and a beta of 0.51.

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. As a group, equities analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were given a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 0.81%. The ex-dividend date was Friday, February 14th. Cencora's dividend payout ratio (DPR) is currently 31.29%.

Insider Activity at Cencora

In related news, Chairman Steven H. Collis sold 14,578 shares of the stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $269.51, for a total value of $3,928,916.78. Following the sale, the chairman now owns 317,913 shares in the company, valued at approximately $85,680,732.63. This trade represents a 4.38 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Elizabeth S. Campbell sold 4,127 shares of Cencora stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $268.28, for a total value of $1,107,191.56. Following the sale, the executive vice president now owns 14,665 shares of the company's stock, valued at approximately $3,934,326.20. This trade represents a 21.96 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 30,675 shares of company stock worth $8,034,778. 10.80% of the stock is owned by corporate insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.